At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Camlipixant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Camlipixant, Dabigatran etexilate, and 1 other intervention for Cough and Healthy. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating potential drug-drug interactions between gemfibrozil (part 1) or dabigatran etexilate (part 2) and camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.
Study Details
Timeline
Phase 1CompletedFinished
202420252026
First PostedJul 2023
Enrollment StartJul 2023
Primary CompletionOct 2023
TodayJul 2026
First PostedJul 25, 2023
Enrollment StartJul 26, 2023
Primary CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.9 years ago
Interventions
Camlipixantdrug
Camlipixant will be administered
Dabigatran etexilatedrug
Dabigatran etexilate will be administered
Gemfibrozildrug
Gemfibrozil will be administered.